Barclays Maintains Overweight on Aspen Aerogels, Lowers Price Target to $13
Benzinga Newsdesk 1 year ago
NewsPrice TargetAnalyst Ratings
Barclays analyst David Anderson maintains Aspen Aerogels (NYSE:ASPN) with a Overweight and lowers the price target from $25 to $13.
Barclays analyst David Anderson maintains Aspen Aerogels (NYSE:ASPN) with a Overweight and lowers the price target from $25 to $13.